There are 2867 resources available
617O - Lemzoparlimab, a differentiated anti-CD47 monoclonal antibody, in combination with azacitidine (AZA) in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS): Initial clinical results
Presenter: Chunkang Chang
Session: Proffered Paper session: Haematological malignancies
Resources:
Abstract
Slides
Webcast
729MO - Final results of the first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in combination with nivolumab in subjects with solid tumors relapsed/refractory to prior anti-PD1/PD-L1 treatment
Presenter: Ignacio Melero
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
LBA61 - HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: A multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC)
Presenter: Liwei Wang
Session: Mini Oral session: GI, upper digestive
Resources:
Abstract
Slides
Webcast
LBA18 - Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial
Presenter: Fabrice André
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Endometrial cancer
Presenter: Domenica Lorusso
Session: Is immunotherapy changing the standard of care in gynaecological cancers?
Resources:
Slides
Webcast
730MO - First-in-human phase I study of INCAGN02390, a TIM-3 monoclonal antibody antagonist in patients with advanced malignancies
Presenter: Martin Gutierrez
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1313O - Assessment of investigational new drugs (INDs) approved in USA and Europe after early phase trials using the ESMO-magnitude of clinical benefit scale (ESMO-MCBS)
Presenter: Justin Moyers
Session: Proffered Paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
1296MO - PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC)
Presenter: Michel Ducreux
Session: Mini Oral session: GI, upper digestive
Resources:
Abstract
Slides
Webcast
LBA39 - Final 5-year results of the phase II, multicenter, randomized, open-label trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (Tx) plus surgery vs immediate surgery in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL)
Presenter: Reinhard Dummer
Session: Proffered Paper session 1: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA19 - Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial
Presenter: Binghe Xu
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast